{"id":872646,"date":"2025-08-07T08:53:20","date_gmt":"2025-08-07T12:53:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-reports-second-quarter-2025-financial-results-and-provides-corporate-update\/"},"modified":"2025-08-07T08:53:20","modified_gmt":"2025-08-07T12:53:20","slug":"metavia-reports-second-quarter-2025-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-reports-second-quarter-2025-financial-results-and-provides-corporate-update\/","title":{"rendered":"MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fourth Quarter of 2025<\/i>\n <\/p>\n

\n Signed AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 Beyond MASH<\/i>\n <\/p>\n

\n
\n $17.6 Million<\/span> in Cash at<\/i>
\n \u00a0End of Second Quarter is E<\/i>
\n xpected to Fund the Company Into 2026<\/i>\n <\/p>\n

\n
\n CAMBRIDGE, Mass.<\/span>
\n <\/span>, Aug. 7, 2025<\/span><\/span> \/PRNewswire\/ — MetaVia Inc.<\/a><\/b>\u00a0(Nasdaq: MTVA),\u00a0a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2025<\/span>, and provided a corporate strategic update.<\/p>\n

\n

\n
\n \"MetaVia
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“During the second quarter and recently, we continued to make significant progress advancing the clinical development of our two next-generation cardiometabolic assets,” stated Hyung Heon Kim<\/span>, President and Chief Executive Officer of MetaVia. “A key milestone was the dosing of the first patient in the 48 mg multiple ascending dose (MAD) Phase 1 trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Most recently, we announced the extension of this 48 mg cohort to 8-weeks, in order to evaluate longer-term early efficacy and safety, while exploring the maximum tolerated dose without the need for titration. Previously reported clinical data from the 32 mg dose cohort highlighted DA-1726’s best-in-class potential, demonstrating a compelling safety and tolerability profile without the need for dose titration. The 48 mg cohort is expected to build on a clear dose-dependent trend in weight reduction seen across the 8 to 32 mg range, potentially unlocking greater efficacy with extended use. We expect the 32 mg dose will serve as the starting point for future clinical trials.”<\/p>\n

“In prior cohorts, DA-1726 at the 32 mg dose demonstrated weight loss (average 4.3%, max 6.3%, p=0.0005 by Day 26), with 83% of patients reporting early satiety. By Day 33, waist circumference decreased by an average of 1.6 inches (max 3.9 inches), aligning with glucagon-driven adipose effects observed in preclinical models. Fasting glucose was reduced by up to 18 mg\/dL without hypoglycemia, highlighting its promise in treating obesity and related metabolic disorders. Cardiovascular safety was also favorable\u2014no QTcF prolongation and reduced heart rate across most cohorts\u2014despite dual agonism. GI side effects were mild, transient, and infrequent, suggesting better tolerability than current GLP-1<\/span> therapies. We look forward to reporting data from the 8-week 48 mg cohort in the fourth quarter of this year. Following our successful private placement for aggregate gross proceeds of $10.0 million<\/span> in May, we remain well-capitalized to reach this milestone, with our runway now extended into 2026.”<\/p>\n

Mr. Kim continued, “In June, we presented new pre-clinical data on DA-1241, a first-in-class oral GPR119 agonist, at the American Diabetes Association’s (ADA) 85th Scientific Sessions. The new data further underscores the potential of combining DA-1241 with an FGF21 analogue, such as Efruxifermin. For the first time, this combination therapy showed synergistic benefits in reducing liver fat, inflammation, and fibrosis, three key drivers of MASH progression. Additionally, our 16-week Phase 2a results, presented at the EASL Congress 2025, highlighted DA-1241’s dual mechanism of action through anti-inflammatory and anti-fibrotic pathways, which demonstrated DA-1241’s hepatoprotective and glucose-regulating effects. Together, these findings reinforce our confidence in DA-1241’s potential as part of a combination approach to effectively address the complex pathology of MASH. We are currently working to schedule an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Based on the strong safety data from the Phase 2a trial, we signed a collaboration agreement with Syntekabio to potentially enhance the value of DA-1241 beyond MASH, by using their DeepMatcher\u00ae AI platform to screen over 1,700 validated protein targets. This approach aims to identify new, high-potential indications while ensuring specificity and reducing off-target risks. We believe this well-tolerated oral candidate can address significant unmet needs and look forward to early insights later this year.”<\/p>\n

\n Second Quarter 2025 and Subsequent Highlights<\/b>\n <\/p>\n